Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9633-9652

  Ansaldi, Filippo ^a,b   Orsi, Andrea ^a   Sticchi, Laura ^a,b   Bruzzone, Bianca ^b   Icardi, Giancarlo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Direct acting antivirals; Hepatitis C virus diagnosis; Hepatitis C virus epidemiology; Hepatitis C virus vaccine; Predictors of response to hepatitis C virus therapy

Indexed keywords

ADJUVANT; BILE SALT EXPORT PUMP; BOCEPREVIR; DANOPREVIR; FALDAPREVIR; HEPATITIS C ANTIGEN; HEPATITIS C VACCINE; INTERLEUKIN 28; LOW DENSITY LIPOPROTEIN RECEPTOR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; TELAPREVIR; VANIPREVIR; VIRUS RNA; VITAMIN D RECEPTOR; BILE ACID; FERRITIN; HEPATITIS ANTIBODY; HEPATITIS C VIRUS ANTIBODY; HEPATITIS C VIRUS RNA; INOSINE TRIPHOSPHATE; INTERLEUKIN 28B; PROTEINASE INHIBITOR; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN; VITAMIN D BINDING PROTEIN; ANTIVIRUS AGENT;

CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ENZYME IMMUNOASSAY; GENE; GENETIC VARIABILITY; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; LIVER FIBROSIS; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULAR DIAGNOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; RAPID TEST; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS GENE; ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ATHEROSCLEROSIS; BILE ACID BLOOD LEVEL; CELLULAR IMMUNITY; FALSE POSITIVE RESULT; FAMILIAL HYPERCHOLESTEROLEMIA; FERRITIN BLOOD LEVEL; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC HETEROGENEITY; HAPLOTYPE; HEPATITIS C RAPID TEST; HUMORAL IMMUNITY; INFECTION PREVENTION; INNATE IMMUNITY; LIMIT OF DETECTION; META ANALYSIS (TOPIC); NUCLEOTIDE SEQUENCE; OBESITY; PHARMACOGENETICS; PREDICTIVE VALUE; PREVALENCE; PRIMARY PREVENTION; RIBAVIRIN INDUCED HEMOLYTIC ANEMIA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEROPREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE; ANTIVIRAL RESISTANCE; DEVELOPING COUNTRY; DRUG EFFECTS; ENDEMIC DISEASES; GENETICS; HEPACIVIRUS; HOST PATHOGEN INTERACTION; PATHOGENICITY; RISK FACTOR;

ANTIVIRAL AGENTS; DEVELOPING COUNTRIES; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; ENDEMIC DISEASES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; PHARMACOGENETICS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84905870295     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9633     Document Type: Review

References (238)

1. Editorial: Non-A, non-B? Lancet 1975; 2: 64-65 [PMID: 49656]
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562]
3. Houghton M. Discovery of the hepatitis C virus. Liver Int 2009; 29 Suppl 1: 82-88 [PMID: 19207970 DOI: 10.1111/j.1478-3231.2008.01925.x]
4. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905 [PMID: 1280771]
5. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500 [PMID: 2509915]
6. van der Poel CL, Reesink HW, Lelie PN, Leentvaar-Kuypers A, Choo QL, Kuo G, Houghton M. Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands. Lancet 1989; 2: 297-298 [PMID: 2569103]
7. Bukh J, Purcell RH, Miller RH. Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci USA 1992; 89: 187-191 [PMID: 1309604]
8. Cha TA, Kolberg J, Irvine B, Stempien M, Beall E, Yano M, Choo QL, Houghton M, Kuo G, Han JH. Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma. J Clin Microbiol 1991; 29: 2528-2534 [PMID: 1663510]
9. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142: 1303-1313.e1 [PMID: 22537437 DOI: 10.1053/j.gastro.2012.02.027]
10. Park Y, Lee JH, Kim BS, Kim do Y, Han KH, Kim HS. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 2010; 48: 2253-2256 [PMID: 20351215 DOI: 10.1128/JCM.01856-09]
11. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, Husain S, Lilly L, Renner E, Mazzulli T. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012; 22: 156-165 [PMID: 22121001 DOI: 10.1002/rmv.717]
12. Descamps V, Op de Beeck A, Plassart C, Brochot E, Franc¸ois C, Helle F, Adler M, Bourgeois N, Degré D, Duverlie G, Castelain S. Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. J Clin Microbiol 2012; 50: 465-468 [PMID: 22162563 DOI: 10.1128/JCM.06503-11]
13. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
14. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Semin Liver Dis 2011; 31: 331-339 [PMID: 22189973 DOI: 10.1055/s-0031-1297922]
15. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology 2012; 55: 1652-1661 [PMID: 22213025 DOI: 10.1002/hep.25556]
16. Di Lorenzo C, Angus AG, Patel AH. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011; 3: 2280-2300 [PMID: 22163345 DOI: 10.3390/v3112280]
17. Barritt AS, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142: 1314-1323.e1 [PMID: 22537438 DOI: 10.1053/j.gastro.2012.02.013]
18. FDA Drug Safety Communication. Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. 19 December 2012. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm332731.htm
19. Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142: 1340-1350.e1 [PMID: 22537441 DOI: 10.1053/j.gastro.2012.02.015]
20. Khaliq S, Jahan S, Pervaiz A. Sequence variability of HCV Core region: important predictors of HCV induced pathogenesis and viral production. Infect Genet Evol 2011; 11: 543-556 [PMID: 21292033 DOI: 10.1016/j.meegid.2011.01.017]
21. Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol 2010; 84: 10159-10168 [PMID: 20668082 DOI: 10.1128/JVI.01180-10]
22. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012; 36: 663-683 [PMID: 22142141 DOI: 10.1111/j.1574-6976.2011.00319.x]
23. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945 [PMID: 16107833]
24. Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H. A look behind closed doors: interaction of persistent viruses with dendritic cells. Nat Rev Microbiol 2010; 8: 350-360 [PMID: 20372157 DOI: 10.1038/nrmicro2332]
25. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011; 60: 268-278 [PMID: 20876777 DOI: 10.1136/gut.2010.212555]
26. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754 [PMID: 19587449 DOI: 10.1172/JCI39133]
27. Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, Holtzman MJ, Chung RT. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol 2006; 80: 9226-9235 [PMID: 16940534]
28. Kumthip K, Chusri P, Jilg N, Zhao L, Fusco DN, Zhao H, Goto K, Cheng D, Schaefer EA, Zhang L, Pantip C, Thongsawat S, O'Brien A, Peng LF, Maneekarn N, Chung RT, Lin W. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 2012; 86: 8581-8591 [PMID: 22674974 DOI: 10.1128/JVI.00533-12]
29. World Health Organization Hepatitis C Fact Sheet 2012. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
30. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47: 1128-1135 [PMID: 18318441 DOI: 10.1002/hep.22165]
31. Lavanchy D . The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
32. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29 [PMID: 14681338]
33. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]
34. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425-427 [PMID: 10645164]
35. Nerrienet E, Pouillot R, Lachenal G, Njouom R, Mfoupouendoun J, Bilong C, Mauclere P, Pasquier C, Ayouba A. Hepatitis C virus infection in cameroon: A cohort-effect. J Med Virol 2005; 76: 208-214 [PMID: 15834878]
36. Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19: 560-567 [PMID: 22762140 DOI: 10.1111/j.1365-2893.2011.01576.x]
37. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci USA 2010; 107: 14757-14762 [PMID: 20696911 DOI: 10.1073/pnas.1008877107]
38. Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection - Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 2012; 61: 545-549 [PMID: 22832935]
39. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-891 [PMID: 10752705]
40. Paez Jimenez A, Sharaf Eldin N, Rimlinger F, El-Daly M, El- Hariri H, El-Hoseiny M, Mohsen A, Mostafa A, Delarocque-Astagneau E, Abdel-Hamid M, Fontanet A, Mohamed MK, Thiers V. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 2010; 59: 1554-1560 [PMID: 20947889 DOI: 10.1136/gut.2009.194266]
41. Plancoulaine S, Mohamed MK, Arafa N, Bakr I, Rekacewicz C, Trégouët DA, Obach D, El Daly M, Thiers V, Féray C, Abdel-Hamid M, Abel L, Fontanet A. Dissection of familial correlations in hepatitis C virus (HCV) seroprevalence suggests intrafamilial viral transmission and genetic predisposition to infection. Gut 2008; 57: 1268-1274 [PMID: 18480169 DOI: 10.1136/gut.2007.140681]
42. Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, Fix AD, Strickland GT. Intrafamilial transmission of hepatitis C in Egypt. Hepatology 2005; 42: 683-687 [PMID: 16032698]
43. Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009; 13: 9-19 [PMID: 18835208 DOI: 10.1016/j.ijid.2008.06.019]
44. Waheed Y, Shafi T, Safi SZ, Qadri I. Hepatitis C virus in Pakistan: a systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009; 15: 5647-5653 [PMID: 19960560]
45. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, Zaer-rezaii H, Amini-Kafiabad S, Maghsudlu M, Pourshams A, Malekzadeh R, Esmaili S. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis 2010; 14 Suppl 3: e113-e116 [PMID: 20362479 DOI: 10.1016/j.ijid.2009.11.032]
46. Alavian SM. Hepatitis C infection in Iran: A review article. Iranian J Clin Infect Dis 2009; 4: 47-59
47. Xia GL, Liu CB, Cao HL, Bi SL, Zhan MY, Su CA, Nan JH, Qi XQ. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hep Comm 1996; 5: 62-73
48. Lu J, Zhou Y, Lin X, Jiang Y, Tian R, Zhang Y, Wu J, Zhang F, Zhang Y, Wang Y, Bi S. General epidemiological parameters of viral hepatitis A, B, C, and E in six regions of China: a cross-sectional study in 2007. PLoS One 2009; 4: e8467 [PMID: 20041146 DOI: 10.1371/journal.pone.0008467]
49. Liu F, Chen K, He Z, Ning T, Pan Y, Cai H, Ke Y. Hepatitis C seroprevalence and associated risk factors, Anyang, China. Emerg Infect Dis 2009; 15: 1819-1822 [PMID: 19891874 DOI: 10.3201/eid1511.090263]
50. Yan Z, Fan K, Wang Y, Fan Y, Tan Z, Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepat Mon 2012; 12: 196-204 [PMID: 22550528 DOI: 10.5812/hepatmon.857]
51. Paez Jimenez A, Mohamed MK, Eldin NS, Seif HA, El Aidi S, Sultan Y, Elsaid N, Rekacewicz C, El-Hoseiny M, El-Daly M, Abdel-Hamid M, Fontanet A. Injection drug use is a risk factor for HCV infection in urban Egypt. PLoS One 2009; 4: e7193 [PMID: 19784363 DOI: 10.1371/journal.pone.0007193]
52. Thaikruea L, Thongsawat S, Maneekarn N, Netski D, Thomas DL, Nelson KE. Risk factors for hepatitis C virus infection among blood donors in northern Thailand. Transfusion 2004; 44: 1433-1440 [PMID: 15383015]
53. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436-2441 [PMID: 17552026]
54. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562 [PMID: 10451460]
55. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-1101 [PMID: 21745274 DOI: 10.1111/j.1478-3231.2011.02494.x]
56. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-782 [PMID: 10706572]
57. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S [PMID: 10653448]
58. Williams IT, Bell BP, Kuhnert W, Alter MJ. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011; 171: 242-248 [PMID: 21325115 DOI: 10.1001/archinternmed.2010.511]
59. The Kirby Institute . HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia. Annual Surveillance Report 2012. Available from: URL: http://www.kirby.unsw.edu.au/sites/default/files/hiv/resources/2012AnnualSurvAnnual.pdf
60. Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, Mc- Gregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91: 228-235 [PMID: 17669601]
61. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K, Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM, Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2: 61-80 [PMID: 21651703 DOI: 10.1111/j.1478-3231.2011.02540.x]
62. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002; 62 Suppl 1: 8-17 [PMID: 11868791]
63. Tanaka Y, Hanada K, Orito E, Akahane Y, Chayama K, Yoshizawa H, Sata M, Ohta N, Miyakawa Y, Gojobori T, Mizokami M. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol 2005; 42: 47-53 [PMID: 15629506]
64. Dalgard O, Jeansson S, Skaug K, Raknerud N, Bell H. Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum. Scand J Gastroenterol 2003; 38: 864-870 [PMID: 12940441]
65. Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, De Angelis D. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health 2012; 22: 187-192 [PMID: 21708792 DOI: 10.1093/eurpub/ckr083]
66. Delarocque-Astagneau E, Pillonel J, De Valk H, Perra A, Laperche S, Desenclos JC. An incident case-control study of modes of hepatitis C virus transmission in France. Ann Epidemiol 2007; 17: 755-762 [PMID: 17728145]
67. Duberg A, Janzon R, Bäck E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill 2008; 13: [PMID: 18761966]
68. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36: 731-737 [PMID: 17693458]
69. European Centre for Disease Prevention and Control (ECDC). Annual epidemiological report on communicable diseases in Europe 2008. Available from: URL: http://ecdc.europa.eu/en/files/pdf/Publications/081215-AER-long-2008.pdf
70. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-162 [PMID: 18022726]
71. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973 [PMID: 16149085]
72. Gottwein JM, Bukh J. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res 2008; 71: 51-133 [PMID: 18585527 DOI: 10.1016/S0065-3527(08)00002-X]
73. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
74. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9: 267-276 [PMID: 18319742 DOI: 10.1038/nrg2323]
75. Chao DT, Abe K, Nguyen MH. Systematic review: epidemiology of hepatitis C genotype 6 and its management. Aliment Pharmacol Ther 2011; 34: 286-296 [PMID: 21623850 DOI: 10.1111/j.1365-2036.2011.04714.x]
76. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19: 449-464 [PMID: 22676357 DOI: 10.1111/j.1365-2893.2012.01617]
77. Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, Chyczewski L. Changing HCV genotypes distribution in Poland - relation to source and time of infection. J Clin Virol 2008; 42: 156-159 [PMID: 18353714 DOI: 10.1016/j.jcv.2008.02.001]
78. Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, Orgulas K, Pruunsild K, Priimägi L, Magnius LO. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol 2007; 79: 374-382 [PMID: 17311333]
79. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13: 19-27 [PMID: 16364078]
80. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005; 3: S97-S101 [PMID: 16234071]
81. Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Alshuth U, Rockstroh JK, Niederau C, Hüppe D. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012; 50: 441-444 [PMID: 22581697 DOI: 10.1055/s-0031-1282072]
82. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91-133 [PMID: 20345213 DOI: 10.3109/10408410903357455]
83. Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5: 496-504 [PMID: 24073301]
84. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, Dillion JF, Flisiak R, Forns X, Frankova S, Goldis A, Goulis I, Halota W, Hunyady B, Lagging M, Largen A, Makara M, Manolakopoulos S, Marcellin P, Marinho RT, Pol S, Poynard T, Puoti M, Sagalova O, Sibbel S, Simon K, Wallace C, Young K, Yurdaydin C, Zuckerman E, Negro F, Zeuzem S. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 Suppl 2: 30-60 [PMID: 21651702 DOI: 10.1111/j.1478-3231.2011.02539.x]
85. Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat 2012; 19 Suppl 1: 42-47 [PMID: 22233413 DOI: 10.1111/j.1365-2893.2011.01523.x]
86. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
87. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014; 59: 2403-2412 [PMID: 24155107 DOI: 10.1002/hep.26905]
88. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359 [PMID: 16905701]
89. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]
90. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, Esteban R, Abdo AA, Harrison SA, Ibrahim N, Cacoub P, Eslam M, Lee SS. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-1262 [PMID: 21316497 DOI: 10.1016/j.jhep.2010.11.016]
91. Lee LY, Tong CY, Wong T, Wilkinson M. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 2012; 66: 342-355 [PMID: 22420497 DOI: 10.1111/j.1742-1241.2012.02895.x]
92. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-622 [PMID: 18838975 DOI: 10.1038/ncpgasthep1274]
93. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
94. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
95. World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. Available from: URL: http://www.who.int/entity/csr/disease/hepatitis/GHP-framework.pdf
96. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355 [PMID: 19759364 DOI: 10.1093/jnci/djp288]
97. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132: 1287-1293 [PMID: 17433322]
98. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. Philadelphia: Lippincott-Raven Publishers, 2007
99. Weiner AJ, Brauer MJ, Rosenblatt J, Richman KH, Tung J, Crawford K, Bonino F, Saracco G, Choo QL, Houghton M. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 1991; 180: 842-848 [PMID: 1846505]
100. Kato N, Sekiya H, Ootsuyama Y, Nakazawa T, Hijikata M, Ohkoshi S, Shimotohno K. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 1993; 67: 3923-3930 [PMID: 7685404]
101. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344 [PMID: 10764648]
102. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714 [PMID: 15939787]
103. Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-938 [PMID: 16107832]
104. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796 [PMID: 15951748]
105. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, Cheng G, McKeating JA, Chisari FV. Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 2006; 80: 11082-11093 [PMID: 16956932]
106. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113 [PMID: 10390360]
107. Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 2006; 9: 416-422 [PMID: 16814596]
108. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 2006; 103: 2310-2315 [PMID: 16461899]
109. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142: 978-988 [PMID: 22248663 DOI: 10.1053/j.gastro.2011.12.055]
110. Podevin P, Carpentier A, Pène V, Aoudjehane L, Carrière M, Zaïdi S, Hernandez C, Calle V, Méritet JF, Scatton O, Dreux M, Cosset FL, Wakita T, Bartenschlager R, Demignot S, Conti F, Rosenberg AR, Calmus Y. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010; 139: 1355-1364 [PMID: 20600021 DOI: 10.1053/j.gastro.2010.06.058]
111. Bukh J . Animal models for the study of hepatitis C virus infection and related liver disease. Gastroenterology 2012; 142: 1279-1287.e3 [PMID: 22537434 DOI: 10.1053/j.gastro.2012.02.016]
112. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-7796 [PMID: 7519785]
113. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, Virata-Theimer ML, Alter HJ, Feinstone S, Major M. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 2009; 106: 7537-7541 [PMID: 19380744 DOI: 10.1073/pnas.0902749106]
114. Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, Krawczynski K, Liang TJ. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology 2011; 54: 1135-1148 [PMID: 21674561 DOI: 10.1002/hep.24489]
115. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204: 1186-1190 [PMID: 21917891 DOI: 10.1093/infdis/jir511]
116. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011; 140: 1334-1344 [PMID: 21237170 DOI: 10.1053/j.gastro.2011.01.001]
117. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 2013; 501: 237-241 [PMID: 23903655 DOI: 10.1038/nature12427]
118. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect Dis 2008; 8: 379-386 [PMID: 18501853 DOI: 10.1016/S1473-3099(08)70126-9]
119. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005; 25: 7-17 [PMID: 15731994]
120. Zou S, Dodd RY, Stramer SL, Strong DM. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351: 751-759 [PMID: 15317888]
121. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759]
122. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-1298 [PMID: 7509068]
123. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 6367-6373 [PMID: 20619382 DOI: 10.1016/j.vaccine.2010.06.084]
124. Houghton M . Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239: 99-108 [PMID: 21198667 DOI: 10.1111/j.1600-065X.2010.00977.x]
125. Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D, Gervase B, Coates S, Houghton M, Basser R. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009; 5: 151-157 [PMID: 19246990]
126. Polakos NK, Drane D, Cox J, Ng P, Selby MJ, Chien D, O' Hagan DT, Houghton M, Paliard X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001; 166: 3589-3598 [PMID: 11207320]
127. Reali E, Houghton M, Abrignani S. Hepatitis C virus vaccines. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 5th ed. Netherlands: Saunders Elsevier, 2008: 1187-1199
128. Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 2013; 57: 1303-1313 [PMID: 23150224 DOI: 10.1002/hep.26132]
129. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 3827-3836 [PMID: 9557666]
130. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA 2003; 100: 6753-6758 [PMID: 12748380]
131. Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ. Immunization with hepatitis C viruslike particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004; 78: 6995-7003 [PMID: 15194776]
132. Elmowalid GA, Qiao M, Jeong SH, Borg BB, Baumert TF, Sapp RK, Hu Z, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104: 8427-8432 [PMID: 17485666]
133. Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J, Jackson DC. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012; 7: e47492 [PMID: 23091628 DOI: 10.1371/journal.pone.0047492]
134. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeG-rand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3: 94ra71 [PMID: 21813755 DOI: 10.1126/scitranslmed.3002330]
135. Reyes-del Valle J, de la Fuente C, Turner MA, Springfeld C, Apte-Sengupta S, Frenzke ME, Forest A, Whidby J, Marcotrigiano J, Rice CM, Cattaneo R. Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol 2012; 86: 11558-11566 [PMID: 22896607 DOI: 10.1128/JVI.01776-12]
136. Chiarella P, Fazio VM, Signori E. Application of electroporation in DNA vaccination protocols. Curr Gene Ther 2010; 10: 281-286 [PMID: 20504275]
137. Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince AM, Sung YC. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005; 42: 1429-1436 [PMID: 16317673]
138. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-1395 [PMID: 18471515 DOI: 10.1053/j.gastro.2008.02.058]
139. Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, Cosset FL, Folgori A, Lee DH, Brotman B, Prince AM. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol 2008; 82: 10896-10905 [PMID: 18753204 DOI: 10.1128/JVI.01179-08]
140. Rollier CS, Paranhos-Baccala G, Verschoor EJ, Verstrepen BE, Drexhage JA, Fagrouch Z, Berland JL, Komurian-Pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VC, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset FL, Spaan WJ, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007; 45: 602-613 [PMID: 17326154]
141. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007; 25: 1452-1463 [PMID: 17098335]
142. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011; 141: 890-899.e1-4 [PMID: 21699798 DOI: 10.1053/j.gastro.2011.06.009]
143. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011; 23: 377-382 [PMID: 21514130 DOI: 10.1016/j.coi.2011.03.006]
144. Liang TJ . Current progress in development of hepatitis C virus vaccines. Nat Med 2013; 19: 869-878 [PMID: 23836237 DOI: 10.1038/nm.3183]
145. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
146. Centers for Disease Control and Prevention (CDC) . Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013; 62: 362-365 [PMID: 23657112]
147. de Leuw P, Sarrazin C, Zeuzem S. How to use virological tools for the optimal management of chronic hepatitis C. Liver Int 2011; 31 Suppl 1: 3-12 [PMID: 21205131 DOI: 10.1111/j.1478-3231.2010.02398.x]
148. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis 2012; 55 Suppl 1: S43-S48 [PMID: 22715213 DOI: 10.1093/cid/cis368]
149. Lin HJ, Lau JY, Lauder IJ, Shi N, Lai CL, Hollinger FB. The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. Virus Res 1993; 30: 27-41 [PMID: 7505514]
150. Barrera JM, Francis B, Ercilla G, Nelles M, Achord D, Darner J, Lee SR. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995; 68: 15-18 [PMID: 7536987]
151. Ansaldi F, Icardi G. Simultaneous detection of anti-HCV antibody and HCV core antigen. Methods Mol Biol 2009; 510: 15-23 [PMID: 19009250 DOI: 10.1007/978-1-59745-394-3-2]
152. Chevaliez S. Virological tools to diagnose and monitor hepatitis C virus infection. Clin Microbiol Infect 2011; 17: 116-121 [PMID: 21054664 DOI: 10.1111/j.1469-0691.2010.03418.x]
153. Coppola N, Pisapia R, Tonziello G, Masiello A, Martini S, Pisaturo M, Messina V, Sagnelli C, Macera M, Signoriello G, Sagnelli E. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-229 [PMID: 19758839 DOI: 10.1016/j.jcv.2009.08.009]
154. Kanno A, Kazuyama Y. Immunoglobulin G antibody avidity assay for serodiagnosis of hepatitis C virus infection. J Med Virol 2002; 68: 229-233 [PMID: 12210412]
155. Smith BD, Teshale E, Jewett A, Weinbaum CM, Neaigus A, Hagan H, Jenness SM, Melville SK, Burt R, Thiede H, Al-Tayyib A, Pannala PR, Miles IW, Oster AM, Smith A, Finlayson T, Bowles KE, Dinenno EA. Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis 2011; 53: 780-786 [PMID: 21921221 DOI: 10.1093/cid/cir499]
156. Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204: 825-831 [PMID: 21849279 DOI: 10.1093/infdis/jir422]
157. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36: 211-218 [PMID: 12085367]
158. Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 2013; 58: 535-540 [PMID: 24041472 DOI: 10.1016/j.jcv.2013.08.028]
159. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48: 1161-1168 [PMID: 20107102 DOI: 10.1128/JCM.01640-09]
160. Moscato GA, Giannelli G, Grandi B, Pieri D, Marsi O, Guarducci I, Batini I, Altomare E, Antonaci S, Capria A, Pellegrini G, Sacco R. Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C. Intervirology 2011; 54: 61-65 [PMID: 20829601 DOI: 10.1159/000318878]
161. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003; 7: 127-137 [PMID: 12691462]
162. Saldanha J, Heath A, Aberham C, Albrecht J, Gentili G, Gessner M, Pisani G. World Health Organization collaborative study to establish a replacement WHO international standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sang 2005; 88: 202-204 [PMID: 15787732]
163. Kessler HH, Hübner M, Konrad PM, Stelzl E, Stübler MM, Baser MH, Santner BI. Genotype impact on HCV RNA levels determined with the VERSANT HCV RNA 1.0 assay (kPCR). J Clin Virol 2013; 58: 522-527 [PMID: 24095028 DOI: 10.1016/j.jcv.2013.09.005]
164. Bouchardeau F, Cantaloube JF, Chevaliez S, Portal C, Razer A, Lefrère JJ, Pawlotsky JM, De Micco P, Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J Clin Microbiol 2007; 45: 1140-1145 [PMID: 17251399]
165. Chevaliez S, Bouvier-Alias M, Vandervenet C, Pawlotsky JM. HCV genotype determination in clinical practice: weaknesses of assays based on the 5'noncoding region and improvement with the core-coding region. Hepatology 2007; 46 Suppl 1: 839A
166. Stelzl E, van der Meer C, Gouw R, Beld M, Grahovac M, Marth E, Kessler HH. Determination of the hepatitis C virus subtype: comparison of sequencing and reverse hybridization assays. Clin Chem Lab Med 2007; 45: 167-170 [PMID: 17311502]
167. Verbeeck J, Stanley MJ, Shieh J, Celis L, Huyck E, Wollants E, Morimoto J, Farrior A, Sablon E, Jankowski-Hennig M, Schaper C, Johnson P, Van Ranst M, Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J Clin Microbiol 2008; 46: 1901-1906 [PMID: 18400913 DOI: 10.1128/JCM.02390-07]
168. Gryadunov D, Nicot F, Dubois M, Mikhailovich V, Zasedatelev A, Izopet J. Hepatitis C virus genotyping using an oligonucleotide microarray based on the NS5B sequence. J Clin Microbiol 2010; 48: 3910-3917 [PMID: 20844214 DOI: 10.1128/JCM.01265-10]
169. Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wede-meyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009; 16: 75-90 [PMID: 18761607 DOI: 10.1111/j.1365-2893.2008.01012.x]
170. Asselah T, Benhamou Y, Marcellin P. Protease and polymerase inhibitors for the treatment of hepatitis C. Liver Int 2009; 29 Suppl 1: 57-67 [PMID: 19207967 DOI: 10.1111/j.1478-3231.2008.01928.x]
171. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-387 [PMID: 19472445]
172. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50: 1709-1718 [PMID: 19787809 DOI: 10.1002/hep.23192]
173. Victrelis TM (boceprevir). Summary of Products Characteristics, 2012. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/ 002332/WC500109786.pdf
174. Incivo TM (telaprevir). Summary of Product Characteristics, 2012. Available from: URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/ 002313/ WC500115529.pdf
175. Thompson AJ, Locarnini SA, Beard MR. Resistance to anti-HCV protease inhibitors. Curr Opin Virol 2011; 1: 599-606 [PMID: 22440917 DOI: 10.1016/j.coviro.2011.10.001]
176. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
177. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428 [PMID: 21696308 DOI: 10.1056/NEJMoa1013086]
178. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55: 1048-1057 [PMID: 22095516 DOI: 10.1002/hep.24791]
179. Vierling JM. Hepatitis C virus viral assays in the directacting antiviral era. Clin Liver Dis 2013; 17: 27-45 [PMID: 23177281 DOI: 10.1016/j.cld.2012.09.002]
180. Pawlotsky JM. Treatment of hepatitis C: how will we use viral kinetics, response-guided therapy? Curr Gastroenterol Rep 2013; 15: 309 [PMID: 23314805 DOI: 10.1007/s11894-012-0309-x]
181. Rosenberg WM, Tanwar S, Trembling P. Complexities of HCV management in the new era of direct-acting antiviral agents. QJM 2014; 107: 17-19 [PMID: 24065837]
182. Cobb B, Pockros PJ, Vilchez RA, Vierling JM. HCV RNA viral load assessments in the era of direct-acting antivirals. Am J Gastroenterol 2013; 108: 471-475 [PMID: 23552304 DOI: 10.1038/ajg.2012.248]
183. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282: 103-107 [PMID: 9756471]
184. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231 [PMID: 9214474]
185. Dahari H, Guedj J, Perelson AS, Layden TJ. Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B. Curr Hepat Rep 2011; 10: 214-227 [PMID: 22180724]
186. Bartenschlager R, Lohmann V. Replication of hepatitis C virus. J Gen Virol 2000; 81: 1631-1648 [PMID: 10859368]
187. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63 [PMID: 7597443]
188. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462 [PMID: 20006612 DOI: 10.1053/j.gastro.2009.11.055]
189. Jacka B, Lamoury F, Simmonds P, Dore GJ, Grebely J, Applegate T. Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS One 2013; 8: e67073 [PMID: 23826196]
190. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007; 46: 631-639 [PMID: 17680654]
191. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-1777 [PMID: 17484874]
192. Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir. Antimicrob Agents Chemother 2014; 58: 698-705 [PMID: 24217701 DOI: 10.1128/AAC.01976-13]
193. Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol 2012; 26: 487-503 [PMID: 23199507 DOI: 10.1016/j.bpg.2012.09.011]
194. Phenotype Working Group, Drug development Advisory Group. Clinically relevant HCV drug resistance mutations figures and tables (updated). Ann Forum Collab HIV Res 2012; 14: 1-8
195. Wyles DL. Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection. Top Antivir Med 2012; 20: 139-145 [PMID: 23154254]
196. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838 [PMID: 19403902 DOI: 10.1056/NEJMoa0806104]
197. Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013; 57: 221-229 [PMID: 23575197 DOI: 10.1093/cid/cit226]
198. Asselah T, Bièche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007; 27: 13-27 [PMID: 17295174]
199. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-S24 [PMID: 16356583]
200. Thio CL . Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis 2008; 12: 713-726, xi [PMID: 18625436 DOI: 10.1016/j.cld.2008.03.002]
201. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun 2004; 5: 237-245 [PMID: 15103322]
202. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 2010; 45: 903-910 [PMID: 20635099 DOI: 10.1007/s00535-010-0287-4]
203. Doyle JS, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. Best Pract Res Clin Gastroenterol 2012; 26: 413-427 [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004]
204. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010; 139: 1865-1876 [PMID: 20950615 DOI: 10.1053/j.gastro.2010.10.004]
205. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2011; 55: 289-298 [PMID: 21147189 DOI: 10.1016/j.jhep.2010.11.019]
206. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801 [PMID: 19759533 DOI: 10.1038/nature08463]
207. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
208. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-145, 1338-145, [PMID: 20060832 DOI: 10.1053/j.gastro.2009.12.056]
209. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]
210. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]
211. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T, Horimoto K, Tanaka Y, Tokunaga K, Mizokami M, Kaneko S. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139: 499-509 [PMID: 20434452 DOI: 10.1053/j.gastro.2010.04.049]
212. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-972 [PMID: 16107837]
213. Tillmann H, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Kullig U, Goebel U, Capka E, Wiegand J, Schiefke I, Spengler U, McCarthy J, Shianna K, Goldstein DB, McHutchison JG, Timm J, Nattermann J, Anti-D Study Group. IL28B polymorphism is associated with jaundice during acute HCV infection and is a strong predictor for spontaneous clearance in the prospective german anti-D cohort. J Hepatol 2010; 52 Suppl 1: S56 [DOI: 10.1016/ S0168-8278(10)60127-4]
214. Grebely J, Petoumenos K, Hellard M, Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W, Lloyd AR, Booth D, Kaldor JM, George J, Dore GJ. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010; 52: 1216-1224 [PMID: 20803561 DOI: 10.1002/hep.23850]
215. Luo Y, Jin C, Ling Z, Mou X, Zhang Q, Xiang C. Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis. Gene 2013; 513: 292-296 [PMID: 23142377 DOI: 10.1016/j.gene.2012.10.030]
216. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55: 1700-1710 [PMID: 22234924 DOI: 10.1002/hep.25582]
217. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53: 336-345 [PMID: 21254181 DOI: 10.1002/hep.24052]
218. Soriano V, Poveda E, Vispo E, Labarga P, Rallón N, Barreiro P. Pharmacogenetics of hepatitis C. J Antimicrob Chemother 2012; 67: 523-529 [PMID: 22194301 DOI: 10.1093/jac/dkr506]
219. Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, Bengtsson L, George S, Seepersaud S, Ramachandran R, Sussky K, Kauffman RS, Botfield M. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011; 54 Suppl 1: S542-S543 [DOI: 10.1016/S0168-8278(11)61371-8]
220. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405-408 [PMID: 20173735 DOI: 10.1038/nature08825]
221. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 2010; 40: 1063-1071 [PMID: 20977565 DOI: 10.1111/j.1872-034X.2010.00741.x]
222. Naggie S, Rallon NI, Benito JM, Morello J, Rodriguez-Novoa S, Clark PJ, Thompson AJ, Shianna KV, Vispo E, McHutchison JG, Goldstein DB, Soriano V. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/ HCV-coinfected patients with all HCV genotypes. J Infect Dis 2012; 205: 376-383 [PMID: 22158703 DOI: 10.1093/infdis/jir754]
223. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 2011; 20: 3507-3516 [PMID: 21659334 DOI: 10.1093/hmg/ddr249]
224. Rau M, Baur K, Geier A. Host genetic variants in the pathogenesis of hepatitis C. Viruses 2012; 4: 3281-3302 [PMID: 23342360]
225. Macías J, Vispo E, Pineda JA, Soriano V. Host genetics. Curr Opin HIV AIDS 2011; 6: 491-500 [PMID: 21918436 DOI: 10.1097/COH.0b013e32834bca2d]
226. Venegas M, Brahm J, Villanueva RA. Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment. Ann Hepatol 2012; 11: 827-837 [PMID: 23109445]
227. Hennig BJ, Hellier S, Frodsham AJ, Zhang L, Klenerman P, Knapp S, Wright M, Thomas HC, Thursz M, Hill AV. Association of low-density lipoprotein receptor polymorphisms and outcome of hepatitis C infection. Genes Immun 2002; 3: 359-367 [PMID: 12209363]
228. Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, Rivero-juárez A, Macías J, Gómez-Mateos J, Rivero A. Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients. AIDS 2011; 25: 1415-1420 [PMID: 21572301 DOI: 10.1097/QAD.0b013e328348a7ac]
229. Fischer DG, Tal N, Novick D, Barak S, Rubinstein M. An antiviral soluble form of the LDL receptor induced by interferon. Science 1993; 262: 250-253 [PMID: 8211145]
230. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, Cabibi D, Licata G, Porcasi R, Marchesini G, Craxí A. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-1167 [PMID: 20162613 DOI: 10.1002/hep.23489]
231. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol 2011; 17: 5184-5190 [PMID: 22215943 DOI: 10.3748/wjg.v17.i47.5184]
232. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One 2012; 7: e40159 [PMID: 22808108 DOI: 10.1371/journal.pone.0040159]
233. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. World J Gastroenterol 2012; 18: 800-805 [PMID: 22371640 DOI: 10.3748/wjg.v18.i8.800]
234. Matsumura T, Kato T, Sugiyama N, Tasaka-Fujita M, Murayama A, Masaki T, Wakita T, Imawari M. 25-Hydroxyvitamin D3 suppresses hepatitis C virus production. Hepatology 2012; 56: 1231-1239 [PMID: 22487892 DOI: 10.1002/hep.25763]
235. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, Zemel R. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54: 1570-1579 [PMID: 21793032 DOI: 10.1002/hep.24575]
236. Lange CM, Miki D, Ochi H, Nischalke HD, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour JF, Gorgievski-Hrisoho M, Heim MH, Malinverni R, Müllhaupt B, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud PY. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One 2013; 8: e64053 [PMID: 23734184 DOI: 10.1371/journal.pone.0064053]
237. Jorquera F, Monte MJ, Guerra J, Sanchez-Campos S, Merayo JA, Olcóz JL, González-Gallego J, Marin JJ. Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol 2005; 20: 547-554 [PMID: 15836702]
238. Iwata R, Stieger B, Mertens JC, Müller T, Baur K, Frei P, Braun J, Vergopoulos A, Martin IV, Schmitt J, Goetze O, Bibert S, Bochud PY, Müllhaupt B, Berg T, Geier A. The role of bile acid retention and a common polymorphism in the ABCB11 gene as host factors affecting antiviral treatment response in chronic hepatitis C. J Viral Hepat 2011; 18: 768-778 [PMID: 20723035 DOI: 10.1111/j.1365-2893.2010.01363.x]